Skip to content

Traditional Chinese and anti-rheumatic drugs for the treatment of rheumatoid arthritis

Integration of Traditional Chinese and Western Medicine treat rheumatoid witharthritis: A prospective, randomized, controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TCC-12002824
Enrollment
Unknown
Registered
2012-12-08
Start date
2008-07-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis with peptic ulcer

Interventions

Acupuncture treatment:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint.
ARD treatment:esomeprazole magnesium enteric-coated tablets ,celecoxib capsules and methotrexate tablets
Combined therapy:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint + oral Shanhuang Wuji decoction

Sponsors

Hospital of Chengdu Military Area Command PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 65 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were as follows: patients with active RA and a TCM syndrome differentiation of arthralgia (aggravated arthralgia with a concomitant syndrome of dampness and heat blocking collaterals); age 45-65 years; a diagnosis of complicating peptic ulcer confirmed by endoscopy; no previous medication with any TCM or Western medicine drugs for the treatment of RA and peptic ulcer; and written, informed consent given prior to enrolment.

Exclusion criteria

Exclusion criteria: Patients were excluded from this study for any of the following reasons: age 65 years; pregnant or lactating, if applicable; known to be allergic to any test medication; complicating Helicobacter pylori infection, GI cancer or GI bleeding; other autoimmune disorders; serious concomitant cardiac, cerebral, hepatic, renal, hematological or endocrine disorders; impaired consciousness or psychiatric disorders; participation in any other clinical studies within the previous three months; or other reasons at the discretion of investigators.

Design outcomes

Primary

MeasureTime frame
serum rheumatoid factor;anti-cyclic citrullinated peptide;erythrocyte sedimentation rate;C-reactive protein;

Countries

China

Contacts

Public ContactLiu Defang
liudefang199@163.com+86 18683958336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026